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Research Article
A collaborative exercise on DNA
methylation based body fluid typing
A collaborative exercise on DNA methylation based body fluid identification was con-
ducted by seven laboratories. For this project, a multiplex methylation SNaPshot reaction
composed of seven CpG markers was used for the identification of four body fluids, in-
cluding blood, saliva, semen, and vaginal fluid. A total of 30 specimens were prepared and
distributed to participating laboratories after thorough testing. The required experiments
included four increasingly complex tasks: (1) CE of a purified single-base extension re-
action product, (2) multiplex PCR of bisulfite-modified DNA, (3) bisulfite conversion of
genomic DNA, and (4) extraction of genomic DNA from body fluid samples. In tasks 2, 3
and 4, one or more mixtures were analyzed, and specimens containing both known and
unknown body fluid sources were used. Six of the laboratories generated consistent body
fluid typing results for specimens of bisulfite-converted DNA and genomic DNA. One
laboratory failed to set up appropriate conditions for capillary analysis of reference single-
base extension products. In general, variation in the values obtained for DNAmethylation
analysis between laboratories increased with the complexity of the required experiments.
However, all laboratories concurred on the interpretation of the DNAmethylation profiles
produced. Although the establishment of interpretational guidelines on DNAmethylation
based body fluid identification has yet to be performed, this study supports the addition of
DNA methylation profiling to forensic body fluid typing.
Keywords:
Body fluid identification / Collaborative exercise / DNA methylation / Forensic
science / Methylation SNaPshot DOI 10.1002/elps.201600256
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
Body fluid identification can be of significant importance
Q2
Q3
Q4
in solving crimes by assisting the triers of fact in the
Correspondence: Hwan Young Lee, Department of Forensic
Medicine, Yonsei University College of Medicine, 50–1 Yonsei-ro,
Seodaemun-gu, Seoul 03722, South Korea
E-mail: hylee192@yuhs.ac and hylee192@gmail.com
Fax: +82-2-362-0860
Abbreviations: mRNA, messenger RNA; SBE, single-base
extension
determination of potential scenarios that may have led to
the deposition of evidentiary material [1]. Recently, molecu-
lar approaches that permit the detection of specificmessenger
RNA (mRNA) andmicro-RNA (miRNA) expression as well as Q5
differential DNA methylation patterns have been intensively
investigated [2]. Among these, the mRNA-based detection
methods have been the most scrutinized, and performance
in terms of reproducibility and sensitivity has been well eval-
uated through a series of large collaborative exercises [2–8].
Colour Online: See the article online to view Figs. 1–4 in colour.
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
2 S.-E. Jung et al. Electrophoresis 2016, 00, 1–8
DNA methylation based body fluid identification has
many advantages when compared to mRNA-based methods,
such as higher specificity, the ability to be inserted into cur-
rent forensic DNA-based testing protocols, and the applicabil-
ity to old caseswhere onlyDNAextracts are available [9].Many
CpGmarkers have been identified,whichproduce differential
DNA methylation patterns when extracted DNA from body
fluids are compared using genome-wide profiling and gene-
specific analysis [10–15]. Three recent publications [13–15]
are particularly notable for reporting a set of CpG markers
that show a methylation signal only in the target body flu-
ids, which can be beneficial to mixed sample analysis. In
particular, two earlier studies [13, 14] reported two markers
in common: cg17610929, suggested to distinguish semen,
and cg06379435, for blood. Moreover, further analysis of ar-
ray data from the two studies revealed that they had another
blood-specific marker, cg08792630, in common. Because the
identification and use of semen-specific CpG markers is not
a problem due to the significant difference in DNA methy-
lation between somatic cells and germ cells, further valida-
tion studies of CpGs specific to other body fluids, such as
vaginal fluid, menstrual blood, saliva, etc., would be needed
for better application of DNA methylation analysis in foren-
sic caseworks. To detect DNA methylation levels at multiple
CpG sites simultaneously, methylation-sensitive restriction
enzyme PCR and the methylation-sensitive single nucleotide
primer extension based approach, generally called methyla-
tion SNaPshot, have been utilized [10,14,15]. In comparison
to methylation-sensitive restriction enzyme PCR, methyla-
tion SNaPshot reactions provide better resolution, and have
been adopted in more recent studies [14–16].
The present collaborative exercise was organized by
Yonsei University College of Medicine in order to evaluate
the robustness and reproducibility of DNA methylation pro-
filing for body fluid identification in seven forensic labora-
tories using kits and chemistries of their own choice and
using their own instrumentation. The multiplex methylation
SNaPshot reaction used by the collaborative laboratories de-
scribed in [14] was modified to include seven CpG markers
that show a methylation signal only in the target body flu-
ids. Since the participating laboratories had varying levels of
experience, especially with DNA methylation profiling using
bisulfite conversion and with the SNaPshot reaction, the goal
was to implement the method and compare the interpreta-
tional results of DNA methylation profiling from the various
laboratories.
2 Materials and methods
2.1 Samples and materials provided
The exercise was divided into four parts such that participants
could easily check the success of experiments performed af-
ter each step of the consecutive procedures (Table 1). Part 1
involved the CE of purified single-base extension (SBE) re-
action products, part 2 involved multiplex PCR of bisulfite
converted DNA, part 3 involved the bisulfite conversion of
genomic DNA, and part 4 involved the DNA extraction of
body fluid samples. As such, the complexity of the required
experiments increased as the participants proceeded through
each part. Specimens, including blood, saliva, semen,
Table 1. Overview of the samples and experiments required in each part of the collaborative exercise
Part Samples Required experiments
1 Purifieda) SBE (single-base extension reaction) productb) CE
Six samples: for each cell typec), single-source samples, cell type indicated
2 Bisulfite converted DNAd) Multiplex PCR, multiplex SBE, CE
Five samples: for each cell typec), single source samples, cell type indicated
Two samples: single source samples, unspecified cell type
One sample: mixture of two body fluids, unspecified cell type
3 Genomic DNAe) Bisulfite conversion, multiplex PCR,
multiplex SBE, CEFive samples: for each cell typec), single source samples, cell type indicated
Two samples: single source samples, unspecified cell type
One sample: mixture of two body fluids, unspecified cell type
4 Body fluid swabs DNA extraction, DNA quantification,
bisulfite conversion, multiplex PCR,
multiplex SBE, CE
Four samples: for each cell typef), single source samples, cell type indicated
One sample: mixture of two body fluids, cell type indicated
Two samples: single source samples, unspecified cell type
One sample: mixture of body fluids, unspecified cell type
a) Purified with SAP-recombinant enzyme.
b) Multiplex SBE reaction product.
c) Semen, blood, vaginal fluid, menstrual blood, and saliva.
d) Bisulfite converted DNA using the Sigma’s Imprint R© DNA modification kit.
e) Genomic DNA extracted using the Qiagen’s QIAamp DNA Mini kit and quantified using the ABI Quantifiler R© Duo DNA quantification
kit.
f) Semen, blood, vaginal fluid, and saliva.
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vaginal fluid, andmenstrual blood, were collected from seven
healthy volunteers using procedures approved by the Institu-
tional Review Board of SeveranceHospital, Yonsei University
in Seoul, Korea. Blood was collected by venipuncture with a
syringe, and 200 L aliquots from EDTA containing tubes
were stored frozen at −20°C. Saliva samples were collected
with the OrageneTM DNA self-collection kit (DNA Genotek,
Ottawa, Canada), and stored at ambient temperature. Freshly
ejaculated semen was collected in plastic cups, and 200 L
aliquots were frozen at −20°C for storage. Vaginal fluid and
menstrual blood were collected using sterile cotton swabs
and allowed to dry at room temperature. The eight body fluid
specimens used in part 4 included four single source samples
and one mixture of indicated origin, and two single source
samples and onemixture of unspecified origin. One hundred
twentymicroliters of freshly ejaculated semen and bloodwere
prepared separately in an Eppendorf microfuge tube with in-
dicated origin. A 200 L of saliva sample was prepared in
the OrageneTM DNA self-collection kit buffer with indicated
origin. Two vaginal swabs and a menstrual blood swab were
obtained from a volunteer. From the two vaginal swabs ob-
tained from a volunteer, one was spiked with 70 L of semen
and both were provided to the collaborative laboratories with
an indication of their origin. The menstrual blood swab was
sent to the collaborative laboratories with unspecified origin.
A semen swab was prepared by dropping 100 L of semen
on a sterile cotton swab, and was provided to the collabora-
tive laboratories with unspecified origin. A body fluidmixture
swab was prepared by adding 100L solution of blood, saliva,
and semen mixed in a ratio of 2:1:1.5 on a sterile cotton swab
and was provided to the collaborative laboratories with un-
specified origin. Treated swabs were allowed to dry at room
temperature and stored at −80°C until sent to participating
laboratories.
For parts 2 and 3, 100 ng of bisulfite-converted DNA
and 200 ng of genomic DNA were prepared for five
single-source samples with an indicated source of ori-
gin, two single-source samples of unspecified origin, and
one mixture of unspecified origin. To prepare mixtures in
parts 2 and 3, the same concentration of each bisulfite-
converted DNA (from blood and saliva) or genomic DNA
(from semen and vaginal fluid) were mixed in a ratio of
1:1.
For part 1, the final products from themethylation SNaP-
shot reaction obtained fromone sample each of semen, blood,
vaginal fluid, and saliva, and two samples from menstrual
bloods were prepared as reference materials.
All samples and PCR primer mixtures were thor-
oughly tested prior to shipment and sent to participat-
ing laboratories on dry ice taking from 1 to 4 days.
When requested, additional reagents such as SNaPshot
kit (Applied Biosystems, Foster City, CA, USA) or en-
zymes necessary for PCR product purification, SBE reac-
tion and purification were sent together on dry ice, and
the ImprintTM DNA Modification kit (Sigma-Aldrich, St.
Louis, MO, USA) for bisulfite conversion was sent at room
temperature.
2.2 DNA extraction, DNA quantification, and
bisulfite conversion
In the organizing laboratory, samples were subjected to DNA
extraction, quantification, and sodium bisulfite treatment.
DNA was extracted from each aliquot of blood, saliva, and
semen or from each swab of vaginal fluid and menstrual
blood using a QIAamp R© DNA Mini kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. Ex-
tracted DNA was quantified using a Quantifiler R© Duo DNA
Quantification kit (Applied Biosystems), and 200 ng of ge-
nomic DNA was bisulfite converted using the ImprintTM
DNAModification kit and eluted with 20L of distilled water.
For preparation of specimens to send to collaborative labora-
tories, an appropriate number of genomic DNA and bisulfite
converted DNA batches were pooled and redistributed into
10 L aliquots, which contained 20 ng/L of genomic DNA
or approximately 10 ng/L of bisulfite converted DNA. The
specified genomic DNA input in bisulfite conversion of part 3
was 100 ng of genomic DNA, but in part 4, the input amount
was not suggested. Example protocols were provided to partic-
ipating laboratories (Supporting Information) as a reference,
but the chemistries and instrumentation to be used were left
for each laboratory to decide.
2.3 Multiplex methylation SNaPshot
The multiplex methylation SNaPshot reaction described in
[14] was modified to include seven CpG markers that show
a methylation signal only in the target body fluids. For this
study, a blood marker, cg01543184, with cross-reactivity to
semen was replaced with a blood marker cg08792630 [13],
and a semen marker cg17621389 with that produced semen-
specific nonmethylation was removed. The resultant mul-
tiplex included two CpGs (SE1 and SE2) for semen, two
CpGs (BL1 and BL3) for blood, two CpGs (VF1 and VF2)
for vaginal fluid, and one CpG (SA1) for saliva (Support-
ing Information); SE1, SE2, BL1, BL3, VF1, VF2, and SA1
represent cg17610929, cg26763284, cg06379435, cg08792630,
cg09765089-231d, cg26079753-7d, and cg09652652-2d, re-
spectively. The multiplex PCR was performed in 20 L re-
actions containing 1 L of bisulfite-converted DNA (10 ng),
3 U of AmpliTaq Gold R© DNA polymerase, 2L of Gold ST*R
10× buffer (Promega, Madison, WI, USA), and PCR primers
(Supporting Information). PCR cycling was conducted using
a VeritiTM Thermal Cycler (Applied Biosystems) under the
following conditions: 95°C for 11 min; 34 cycles of 94°C for
20 s, 56°C for 60 s, and 72°C for 30 s; and a final extension
at 72°C for 7 min. Then, 5 L of PCR products were purified
with 1 L of ExoSAP-IT (USB, Cleveland, OH, USA) by in-
cubation at 37°C for 45 min followed by heat inactivation at
80°C for 15 min. Multiplex SBE reaction was performed us-
ing 1 L of purified PCR products, SBE primers (Supporting
Information), and a SNaPshotTM kit according to the man-
ufacturer’s instructions. The final extension products were
purified with SAP-Recombinant (USB) enzyme. Large batch
of 5× PCR primer and 10× SBE primer stocks were prepared
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and aliquoted to provide all laboratories with the same primer
mixtures. The specified bisulfite-converted DNA input for the
multiplex PCR of parts 2 and 3 was 10 ng; in part 4, the input
amount was not suggested. Example protocols were provided
to participating laboratories (Supporting Information), but a
choice was given regarding which PCR buffers and amplicon
purification methods were to be used.
2.4 CE and analysis of DNA methylation profiles
In the organizing laboratory, the extension products were an-
alyzed using the ABI PRISM 3130xl Genetic Analyzer and
GeneScan software 3.1 (Applied Biosystems). In participat-
ing laboratories, samples were injected and run according
to conditions of choice on various types of standard genetic
analyzers (Supporting Information Table 2). For the analysis
of DNA methylation profiles, participating laboratories were
requested to report peak heights observed from the electro-
pherograms and to calculate percentage methylation values
(0–100%) at each CpG site by dividing nucleotide G intensity
(detection of unconverted methylated cytosine on the reverse
strand) by nucleotide G plus nucleotide A intensity (detection
of converted unmethylated cytosine on the reverse strand).
Then, body fluid typing results were reported in reference to
the electrophoretic results of SBE products in part 1.
3 Results and discussion
3.1 Participating laboratories
Seven laboratories including the organizing laboratory
participated in this exercise. The participating labo-
ratories varied in experience with regard to DNA
methylation analyses. Two laboratories indicated they were
beginners at DNA methylation testing; two other laborato-
ries, advanced beginners; one laboratory, an experienced re-
searcher; and two other laboratories, experts. The participat-
ing laboratories were also asked to complete a questionnaire
describing the kits, chemicals, quantities, and instrumenta-
tion they used (Supporting Information Table 2). The seven
laboratories used four different kits for DNA extraction, five
different quantification methods, two different kits for bisul-
fite conversion, two different PCR buffers for multiplex PCR,
three different thermocyclers, three different genetic analyz-
ers, and three different analytical software and five different
analytical settings. The diversity of instrumentation and re-
spective analysis tools emphasizes the importance of such
collaborative exercises in order to evaluate the robustness of
implementation of methods in different laboratories.
3.2 Exercise tasks: Parts 1–4
The collaborative exercise started with part 1, where puri-
fied SBE products are analyzed with CE. Analysis of the fi-
nal multiplex methylation SNaPshot products from various
body fluid samples provided references to the following data
interpretation and enabled adjustment of the genetic analyzer
setting if necessary. Six of the seven laboratories reported very
similar results in part 1 (Fig. 1). One laboratory (laboratory 4)
had, on average, fourfold higher peaks than the organizing
laboratory with low nonspecific peaks that seemed to be due
to the use of higher injection settings. Because of failure in
adjusting the genetic analyzer setting and unsuccessful en-
zyme treatment to purify PCR products in the subsequent
parts 2–4 at laboratory 4, the results discussed in this report
will only include data from the remaining six laboratories.
The methylation percentages at each CpG site were simi-
lar among the laboratories, but two laboratories using an
ABI PRISM 310 genetic analyzer showed somewhat lower
Figure 1. DNA methylation profiling results of part 1 conducted with the final SBE products of the multiplex methylation SNaPshot
reaction. DNA methylation was recorded as a percentage value by dividing nucleotide G intensity by nucleotide G plus nucleotide A.
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methylation percentages. In addition, it seems that because
two types of menstrual blood of which one had the same pro-
file as vaginal fluid (menstrual blood type 1) were provided
as references in part 1, participating laboratories had diffi-
culty in inferring the sample origin with the profile of vaginal
fluid; in this case, some laboratories reported the origin of the
sample to be either vaginal fluid or menstrual blood, while
others reported it to be vaginal fluid or menstrual blood (Sup-
porting Information Table 3). As such, a distinction between
vaginal fluid and menstrual blood could not be provided for
the reports regarding parts 2–4.
In part 2, bisulfite-converted genomic DNA of semen,
blood, vaginal fluid, menstrual blood, and saliva with known
body fluid origin, and three other samples with unspecified
origin of which two were single source and one was amixture
allowed us to test the proficiency of the participating labora-
tories in performing the SNaPshot reaction. Four of the six
laboratories reported methylation signals only at target body
fluid specific CpG markers with correct body fluid typing re-
sults (Fig. 2). Two laboratories reported additional low-level
methylation signals at SE1, BL1, and SA1 markers, but these
results did not affect correct interpretation of the body fluid
typing results (Supporting Information Table 3). These sig-
nals had low methylation percentages, mostly less than 15%.
For example, the two lowest methylation signals from labo-
ratory 6 were 100 and 94 rfu corresponding to 6.7 and 8.1%
methylation percentages at BL1 and SA1 CpG sites, respec-
tively. Therefore, all six laboratories properly performed and
implemented themultiplex SNaPshot reactions with 10 ng of
bisulfite converted DNA.
For part 3, genomic DNA from semen, blood, vaginal
fluid, menstrual blood, and saliva and three genomic DNA
samples of unspecified origin were provided to test each labo-
ratory’s proficiency in bisulfite conversion. The participating
laboratories were asked to treat 100 ng of genomic DNA with
a bisulfite conversion kit of choice and to perform multi-
plex methylation SNaPshot reactions with a 1/10 portion of
the eluted bisulfite-converted DNA. Two kits were used in
bisulfite conversion (Supporting Information Table 2), but
no significant difference was observed between the results.
As in part 2, the same four laboratories reported methylation
signals only at target body fluid specific CpG markers with
correct body fluid typing results (Fig. 3). Two laboratories
(laboratories 5 and 6) reported sporadic methylation signals
at the BL1 or BL3 markers in semen, menstrual blood, and
in the mixture of semen and vaginal fluid. These peaks were
generally low in methylation percentage, that is, less than
15%, and did not affect the correct interpretation of body
fluid typing results. However, the methylation percentages at
each target CpG site showed higher variation among labora-
tories in part 3 when comparing to parts 1 and 2. Laboratory 3
reported no signal at the BL3 marker in a sample that was
most likely a result of PCR failure at this site; however, it did
not affect the identification of body fluid type. In addition,
laboratory 6 reported a high methylation percentage (35.6%)
at the BL1 site in the mixture of semen and vaginal fluid,
leading to a body fluid typing result of a mixture of semen
and menstrual blood (Supporting Information Table 3). In
most cases, laboratories concurred on the expected interpre-
tation of the results reported among themwith genomicDNA
and bisulfite-converted DNA. This result suggests that DNA
methylation based body fluid identification using multiplex
methylation SNaPshot and bisulfite conversion of genomic
DNA could be successfully incorporated into forensic labora-
tory workflow.
In part 4, various body fluid samples with and without
specified origin were provided. Specimens were subjected to
DNAextraction, quantification, bisulfite conversion, andmul-
tiplex methylation SNaPshot reaction using various method-
ologies according to each laboratory’s preference. Three DNA
Figure 2. DNA methylation profiling results of part 2 conducted with bisulfite-converted DNA. Part 2 results show the proficiency of each
laboratory in SBE reaction analysis. (Un) indicates samples provided with unspecified body fluid origin.
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Figure 3. DNAmethylation profiling results of part 3 conducted with genomic DNA. Part 3 results show the proficiency of each laboratory
in bisulfite conversion. (Un) indicates samples provided with unspecified body fluid origin.
extraction kits and four quantification methods were used
by the six different laboratories. Sufficient amounts of DNA
were obtained from most of the laboratories, but relatively
small yields of DNA were obtained in one of the laboratories
using an automatic DNA extraction system (laboratory 6).
Various amounts of DNA were subjected to bisulfite conver-
sion and 1/10 or 1/20 of the volume of eluted bisulfite con-
verted DNA was amplified in a subsequent multiplex methy-
lation SNaPshot reaction. The resultant amplified bisulfite
converted DNA varied in amount from 0.8 to 20 ng. Of the
six laboratories being evaluated, five laboratories produced ac-
ceptable results with the correct body fluid identification. The
sixth laboratory (laboratory 5) failed to obtain electrophoretic
results from a few specimens, but produced correct results
from the others (Supporting Information Table 3). The five
laboratories reported methylation signals only at target body
fluid specific CpGmarkers except for amenstrual blood swab
with unspecified origin (Fig. 4). For this sample, laboratory 6
produced unexpected methylation signals at SE1 and BL1
CpGmarkers, and laboratory 7 showedmethylation signals at
BL1 and BL3 CpG markers. However, these methylation sig-
nals were all less than 10%, and had no adverse effect on data
interpretation since both laboratories reported the specimens
to be either vaginal fluid or menstrual blood. Laboratory 5 did
Figure 4. DNA methylation profiling results of part 4 with body fluid samples. Part 4 results show the proficiency of each laboratory in
the entire DNA methylation based body fluid typing procedure ranging from DNA extraction to CE. (Un) indicates samples provided with
unspecified body fluid origin.
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not get body fluid typing results from three samples with in-
dicated origin. Since certain amounts of DNA were extracted
and quantified from these three samples, failure seems to
have occurred in the recovery of bisulfite converted DNA or
in PCR amplification. This laboratory also reported “incon-
clusive” for a mixture swab with a methylation signal only at
SE1, BL3, and SA1. However, additional lowmethylation sig-
nals at SE2 and BL1 (50 rfu; data not shown) suggested the
presence of semen, blood, and saliva in this sample. In this
exercise, the most experienced laboratories produced better
DNA methylation profiles and interpretation results. How-
ever, even the laboratories that varied from less experienced
to beginners in DNAmethylation analysis produced success-
ful body fluid typing results, providing strong evidence for the
potential application of DNAmethylation profiling for use in
forensic body fluid typing.
4 Concluding remarks
This collaborative exercise aimed to examine the possibility
of incorporating DNA methylation based body fluid identifi-
cationmethods into forensic case-work workflow.Most of the
participating laboratories reported consistent results for mix-
tures as well as for single-source samples with the use of their
own laboratory equipment and different kits and chemicals of
choice, which demonstrate the usefulness of this application
of DNA methylation profiling in forensic body fluid typing.
In this study, we found that certain laboratories reported low
but detectable methylation signals at unexpected CpG sites,
and there were variations in DNA methylation percentages
among laboratories. Because these unexpected methylation
signals were frequently at less than 10% methylation and
sometimes lower than 100 rfu, we recommend that in the
future an appropriate detection threshold in terms of relative
fluorescence units and percent of methylation, for example,
Q6 more than 100 rfu and 10% methylation, should be applied.
As for the methylation variation, this is not an unexpected
result given that the participating laboratories used a variety
of methods and instrumentation. It is important to note that
the seven CpGs used in this multiplex provide on–off signal
variations in results that can alleviate the effect of methyla-
tion variation among laboratories. Because it is not possible
to differentiate vaginal fluid and menstrual blood with the
present multiplex methylation SNaPshot system, the addi-
tion of new menstrual blood specific CpG markers to the
multiplex system is needed for better identification of body
fluids. In addition, with the use of two or more CpGmarkers
for each target body fluid being preferred, it is evident that
there is also a need to identify more CpGs that are specific
to saliva. If possible, the multiplex system should be supple-
mented in the future with more CpG markers to have two
or more CpGs for each body fluid and consequently increase
the accuracy of the identification of body fluids.While routine
use of DNAmethylation based body fluid typing and identifi-
cation assays may yet require further tests for sensitivity and
specificity, this study demonstrates thatmethylation profiling
canbe successfully implemented in forensic laboratories once
clear guidelines are set for data interpretation.
This research was supported by theMinistry of Public Admin-
istration and Security, Republic of Korea through the National Q7
Forensic Service (grant nos. 1315000435 and 1315000544). B.
M. and J. A. were supported in part through funding provided by
award 2012-D1-BX-K018 from the National Institute of Justice,
USA. Points of view in the document are those of the authors and
do not necessarily represent the official view of the U.S. Depart-
ment of Justice.
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